The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much ...
Semaglutide belongs to a class of prescription medications that mimic a hormone your body naturally produces after you eat. This hormone helps your pancreas make insulin, which lowers your blood sugar ...
A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...
Novo Nordisk, the maker of the semaglutide products Ozempic and Wegovy, has filed lawsuits against 40 pharmacies, spas and ...
By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...
20h
The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...
An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...
Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...
Editorial writers delve into these public health issues.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback